Tourmaline Bio CEO Sandeep Kulkarni and Talaris interim CEO Mary Kay Fenton
June 22, 2023 09:54 AM EDT
Financing
Startups
Deals

Tour­ma­line Bio re­verse merges in­to Ta­laris and rais­es funds to tar­get thy­roid eye dis­ease and phar­ma ri­vals

Kyle LaHucik

Senior Reporter

Ta­laris Ther­a­peu­tics will hand over its spot on the Nas­daq to Tour­ma­line Bio in a re­verse merg­er to fund tri­als of an ex-Pfiz­er drug it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times